Status:
RECRUITING
Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Post-craniotomy
Pain
Eligibility:
All Genders
18-64 years
Phase:
NA
Brief Summary
Post-craniotomy pain is common and often associated with poor outcomes. Flurbiprofen axetil (FA) is an injectable NSAID for postoperative analgesia, however, the impact of local FA, remains elusive on...
Eligibility Criteria
Inclusion
- Age 18-64 years;
- ASA physical status of I - II;
- Scheduled for craniotomy under general anesthesia;
- Anticipated tracheal extubation, recovery of consciousness and orientation within 2 hours after craniotomy.
Exclusion
- Glasgow Coma Scale \<15;
- Unable to use the PCIA device or comprehend the pain NRS;
- History of opioid dependence, chronic headache or intake of any drugs with known analgesic properties within the 24 hours before surgery;
- Any contraindication to flurbiprofen axetil, such as gastrointestinal ulcer, coagulation disorders, renal dysfunction, heart failure and ischemic heart disease;
- History of allergy to any drug used in the study.
Key Trial Info
Start Date :
October 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 15 2026
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT07209345
Start Date
October 15 2025
End Date
October 15 2026
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, China